NNZ 2591, a synthetic analogue of cyclic glycine-proline (cGP), exhibits oral activity and the ability to cross the blood-brain barrier. This compound demonstrates neuroprotective properties following ischemic brain injury and improves motor function in a rat model of Parkinson's disease. NNZ 2591 holds research potential for ischemic brain injury and Angelman syndrome [1] [2] [3].

NNZ 2591 at a dosage of 30 mg/kg administered orally (p.o.) blocked scopolamine-induced amnesia in rats [1]. Intracerebroventricular (i.c.v.) injection of NNZ 2591 at concentrations of 2, 20, and 100 ng/rat demonstrated neuroprotective effects [2]. Subcutaneous (s.c.) administration of NNZ 2591 at 3 mg/kg daily for five days offered complete brain injury prevention and significantly improved the left/right (L/R) touch response time ratio in rats at 5 days post-injury [2].